Institute of Neurological Recovery 1877 S. Federal Hwy. Suite 110 Boca Raton, FL 33432 Phone: +1 (561) 353‑9707.
The Institute of Neurological Recovery® (INR®). A decade of pioneering discoveries in medicine. The INR utilizes the pioneering, patented perispinal etanercept (PSE) off-label treatment methods invented by its founder and Medical Director, Edward Tobinick, M.D. The contents of this website, including text, images, and videos are ©2021 INR PLLC, all rights reserved.
The predicted shapes still need to be confirmed in the lab, Ellis told Technology Review. If the results hold up, they will rapidly push forward the study of the proteome, or the proteins in a given organism. DeepMind researchers published their open-source code and laid out the method in two peer-reviewed papers published in Nature last week.
And in 20 other animals often studied by science, too.
AlphaFold 2 paper and code is finally released. This post aims to inspire new generations of Machine Learning (ML) engineers to focus on foundational biological problems.
This post is a collection of core concepts to finally grasp AlphaFold2-like stuff. Our goal is to make this blog post as self-complete as possible in terms of biology. Thus in this article, you will learn about:
Black short-haired kitty Astra, one of millions of pets acquired during the COVID-19 pandemic last year, had to go without salmon-flavored Whiskas treats that were sold out at stores in New Orleans this month.
A variety of new and promising cancer immunotherapy treatments are only available to patients in clinical trials. Help speed the development of potentially lifesaving drugs. Discover trials for which you or a loved one may be eligible with the CRI Immunotherapy Clinical Trial Finder.
Psoriasis is a lifelong, autoimmune inflammatory disease. It often appears as a skin condition, but it is a systemic condition that can affect many parts of the body.
Psoriasis often causes skin lesions, but also a higher risk of other conditions, such as celiac, inflammatory bowel disease, and mental health issues. Find out more.
This study builds on an earlier paper by the Rothstein lab that looked at the most common genetic cause of ALS, a mutation in the C9orf72 gene (also referred to as the “C9 mutation”). There, they showed that the C9 mutation produced defects in a structure called the nuclear pore that is responsible for moving proteins and other molecules in and out of the nucleus of cells.
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive and fatal degenerative disease affecting the nerve cells in the brain and spinal cord responsible for controlling voluntary muscle movement. “Sporadic” or non-inherited ALS, accounts for roughly 90% percent of cases, and 10% of cases are due to known genetic mutations. By studying lab-grown neurons derived from skin or blood cells from 10 normal controls, eight with an ALS causing mutation, and 17 with non-inherited ALS, researchers have found a possible starting point for the dysfunction that causes the disease. The study, which was published in Science Translational Medicine, was funded in part by the National Institute for Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health.
Using a library of ALS patient-derived cells, the research team led by Jeffrey Rothstein, M.D., Ph.D., at Johns Hopkins University School of Medicine, Baltimore, developed induced pluripotent stem cell (iPSC)-derived neurons from the patients’ cultured cells to discover a common defect regardless of whether the cell came from persons with inherited or non-inherited ALS. They report that in ALS nerve cells, there is an accumulation of a protein called CHMP7 in the nucleus of cultured nerve cells as well as in ALS samples from the brain region that controls movement. Treatments that decrease the amount of CHMP7 in the cultured cells prevented a series of abnormalities that are characteristic of ALS.
“There is considerable interest in identifying new therapeutic targets for ALS, particularly for the sporadic form of the disorder,” said Amelie Gubitz, Ph.D., program director, NINDS. “Gene-targeting strategies like the one shown here now allow us to move from biological discovery straight to therapy development.”
A company that makes an implantable brain-computer interface (BCI) has been given the go-ahead by the Food and Drug Administration to run a clinical trial with human patients. Synchron plans to start an early feasibility study of its Stentrode implant later this year at Mount Sinai Hospital, New York with six subjects. The company said it will assess the device’s “safety and efficacy in patients with severe paralysis.” https://www.engadget.com/fda-brain-computer-interface-clinical-trial-synchron-stentrode-190232289.html?src=rss
A company that makes an implantable has been given the go-ahead by the Food and Drug Administration to run a clinical trial with human patients. Synchron plans to start an early feasibility study of its Stentrode implant later this year at Mount Sinai Hospital, New York with six subjects. The company said it will assess the device’s “safety and efficacy in patients with severe paralysis.”
Synchron received the FDA’s green light ahead of competitors like Elon Musk’s. Before such companies can sell BCIs commercially in the US, they need to prove that the devices work and are safe. The FDA will provide guidance for trials of BCI devices for patients with paralysis or amputation during a webinar on Thursday.
Another clinical trial of Stentrode is underway in Australia. Four patients have received the implant, which is being used “for data transfer from motor cortex to control digital devices,” Synchron said. According to data published in the Journal of NeuroInterventional Surgery, two of the patients were able to control their computer with their thoughts. They completed work-related tasks, sent text messages and emails and did online banking and shopping.
CRISPR reached a big milestone this year by treating a disease inside the body—here’s what’s next for the technology.
Posted in biotech/medical, computing, Elon Musk, neuroscience | Leave a Comment on This 20-person biotech firm just beat Elon Musk’s Neuralink in getting the OK to test brain chip implants in humans with paralysis
Synchron has beat rival Neuralink to human trials of its “implantable brain computer interface.”
The chip will be studied in six patients later this year as a possible aid for paralyzed people.
Elon Musk previously used Neuralink’s chip in a monkey, which then played video games with its mind.
Synchron beat out rival Neuralink, led by Elon Musk, to get the FDA go-ahead for human trials of a chip implant that makes a brain-computer interface.
